Regeneron, Sanofi Report FDA Approval Of Kevzara (Sarilumab) For Treatment Of Patients Weighing 63 Kg Or Greater With Active Polyarticular Juvenile Idiopathic Arthritis
Regeneron, Sanofi Report FDA Approval Of Kevzara (Sarilumab) For Treatment Of Patients Weighing 63 Kg Or Greater With Active Polyarticular Juvenile Idiopathic Arthritis
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.